Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/18/2026

1. XENE
2. SPY
3. HUBS
4. ONON
5. AAPL
6. NUE
7. AZN
8. TRMD
9. AUTO
10. BCBP

Go back to Tenax Therapeutics Announces Topline Results from Phase 3 LEVEL Clinical Trial of TNX-103 in Patients with PH-HFpEF
(NASDAQ: TENX) Delayed: 1.95 +0.09 (4.84%)
Previous Close $1.86    52 Week High $3.40 
Open $1.92    52 Week Low $1.34 
Day High $1.97    P/E N/A 
Day Low $1.85    EPS $0.00 
Volume 3,352,185